Adaptive Biotechnologies
ADPT
300 hedge funds and large institutions have $3.34B invested in Adaptive Biotechnologies in 2026 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 109 increasing their positions, 89 reducing their positions, and 42 closing their positions.
20,966% more call options, than puts
Call options by funds: $146M | Put options by funds: $691K
58% more capital invested
Capital invested by funds: $2.11B → $3.34B (+$1.23B)
22% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 89
17% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 42
1% more funds holding
Funds holding: 298 → 300 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.36% less ownership
Funds ownership: 98.67% → 97.31% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$40.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.5M |
| 3 |
BlackRock
New York
|
+$28.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.8M |
| 5 |
PA
Perceptive Advisors
New York
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$29.6M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
-$25.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$20.8M |
| 4 |
CFM
Capricorn Fund Managers
London,
United Kingdom
|
-$19.4M |
| 5 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
-$18.3M |
ADPT Hedge Fund Activity: Q2 2026 in Review
300 of the 8,298 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2026, worth a combined $3.34B — up 58% from $2.11B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ADPT positions and 42 closed out — a net gain of 7 holders — while 109 added to existing stakes and 89 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $40.8M. The largest seller was Ameriprise, cutting an estimated $29.6M.
- 300 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2026, up from 298 in Q1 2026.
- Funds reported $3.34B of Adaptive Biotechnologies stock for Q2 2026, up 58% quarter-over-quarter.
- 49 funds opened new Adaptive Biotechnologies positions in Q2 2026 and 42 closed out, a net change of +7 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2026 was D.E. Shaw & Co, an estimated $40.8M added.
- The largest Adaptive Biotechnologies seller in Q2 2026 was Ameriprise, an estimated $29.6M sold.
Based on aggregated 13F filings for Q2 2026.